|Security||OCLS / Oculus Innovative Sciences, Inc. (83558L105)|
|Industry||Surgical and Medical Instruments and Apparatus|
|Institutional Shares||807,204 - 12.57%|
|Common Shares Outstanding||6,421,239 shares (as of 2018-03-31)|
|Institutional Value||$ 3,139,000 USD|
OCLSW / Oculus Innovative Sciences, Inc.|
SNOA / Sonoma Pharmaceuticals, Inc.
Institutional Stock Ownership and Shareholders()
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) has 31 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 807,204 shares.
Largest shareholders include
Bard Associates Inc, Vanguard Group Inc, Sabby Management, LLC, Renaissance Technologies LLC, JW Asset Management, LLC, Janus Capital Management Llc, BlackRock Inc., BlackRock Institutional Trust Company, N.A., National Asset Management, Inc., and Deutsche Bank Ag\.
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/ocls"><img src="https://images.fintel.io/us-ocls-so.png" alt="OCLS / Oculus Innovative Sciences, Inc. Institutional Ownership"><a>
|BlackRock Advisors LLC||20,202||0||-100.00||5||0||-100.00|
|BlackRock Fund Advisors||1,009||1,549||53.52||4||8||100.00|
|BARD ASSOCIATES INC||334,199||327,949||-1.87||1,835||1,207||-34.22|
|Gradient Investments LLC||285||1|
|LADENBURG THALMANN FINANCIAL SERVICES INC||3,853||3,853||0.00||21||15||-28.57|
|ROYAL BANK OF CANADA||7||7||0.00||0||0|
|WELLS FARGO & COMPANY/MN||1,014||1,014||0.00||6||4||-33.33|
|Renaissance Technologies LLC||58,602||58,915||0.53||319||217||-31.97|
|BANK OF AMERICA CORP /DE/||540||540||0.00||3||2||-33.33|
|MetLife Securities, Inc||88||88||0.00||0||0|
|RAYMOND JAMES & ASSOCIATES||0||11,041||0||41|
|Blackhawk Capital Partners Llc.||485||485||0.00||3||2||-33.33|
|JW Asset Management, LLC||40,951||40,951||0.00||223||151||-32.29|
|JANUS CAPITAL MANAGEMENT LLC||26,873||37,926||41.13||135||272||101.48|
|BlackRock Institutional Trust Company, N.A.||25,523||0||-100.00||111||0||-100.00|
|National Asset Management, Inc.||14,802||22,420||51.47||81||83||2.47|
|SEI INVESTMENTS CO||4||4||0.00||0||0|
|Hartford Financial Management Inc.||500||500||0.00||2||1||-50.00|
|OPTIMUM INVESTMENT ADVISORS||12||0|
|DEUTSCHE BANK AG\||25,141||20,293||-19.28||137||74||-45.99|
|UBS Group AG||4,444||4,603||3.58||24||17||-29.17|
|VANGUARD GROUP INC||86,197||101,347||17.58||473||373||-21.14|
|GEODE CAPITAL MANAGEMENT, LLC||13,177||13,177||0.00||72||48||-33.33|
|Premia Global Advisors, Llc||10,000||36|
|PANAGORA ASSET MANAGEMENT INC||11,919||44|
|Sabby Management, LLC||69,200||255|
|NORTHERN OAK WEALTH MANAGEMENT INC||117||117||0.00||1||0||-100.00|
|BlackRock Institutional Trust Company, N.A.||25,523||129|
|WADE G W & INC||11,000||11,158||1.44||60||41||-31.67|
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET